CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

Inclusion Criteria: * Naïve patients * Type 1 or type 2 Choroidal NeoVascularization (CNV) * Age ≥ 55 years * Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD) * At the time of inclusion, multimodal imaging should reveal exudative features * Exudative AMD diagnosis established between 1 and 7 days before inclusion * Monitored monthly * Loading phase then bimonthly retreatment. * Signed Informed Consent. * Patient covered by the French Health Insurance Exclusion Criteria: * Polypoidal choroidal vasculopathy * Type 3 neovascularization * Choroidal neovascularization attributable to causes other than AMD * Macular hematoma * Pigment epithelial detachment higher than 150µm * Fibrosis \> 50% lesion on fundus color photography, fibroglial scar * Media opacity annoying acquisition * Retinal vascular occlusion * Diabetic retinopathy * Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies, * Refractive error \>-6D * Active intraocular inflammation in the study eye * Patient who does not meet the local indication criteria for Eylea® treatment. Contraindications listed in the SmPCs must be taken into account * Patient taking part in an interventional study at the time of enrolment. * Any history of allergy to the antiseptic used during preparation of the eye for the IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine). * Pregnant and lactating women * Stroke and/or myocardial infarction 3 months before in…